Wednesday, July 8, 2026

pharma · Obesity · Obesity With Diabetes · KLRA

Kailera Therapeutics

Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker KLRA. Primary therapeutic focus areas include Obesity, Obesity With Diabetes. NovaPharmaNews links 7 clinical pr

Waltham, USA HQ
2024 Founded
153 Employees
Public company Type
KLRA · NYSE Ticker
Company details
Clinical program

KAI-9531

Phase 1 · small molecule · Healthy Volunteers

KAI-9531 for Healthy Volunteers is a Phase 1 program (small_molecule) at Kailera Therapeutics with 1 ClinicalTrials.gov record(s).

← All Kailera Therapeutics projects Phase 1 small molecule completed

Internal code K9531-1102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Kailera Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1

Clinical trials